--- title: "09:24 ETTigerlily Foundation Collaborates with Bristol Myers Squibb to Advance Clinical Trial Access and Equity" type: "News" locale: "en" url: "https://longbridge.com/en/news/286573689.md" description: "Tigerlily Foundation has partnered with Bristol Myers Squibb to enhance access to clinical trials for young women, particularly women of color. This collaboration aims to reduce barriers to participation and increase awareness through the ONE in a MILLION campaign, which seeks to educate one million women about clinical trials. The initiative emphasizes the importance of diversity in research to improve health equity and treatment effectiveness." datetime: "2026-05-15T13:25:39.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286573689.md) - [en](https://longbridge.com/en/news/286573689.md) - [zh-HK](https://longbridge.com/zh-HK/news/286573689.md) --- # 09:24 ETTigerlily Foundation Collaborates with Bristol Myers Squibb to Advance Clinical Trial Access and Equity National Breast Cancer Nonprofit Highlights Efforts to Reduce Barriers for Patients, Especially Women of Color , /PRNewswire/ -- Tigerlily Foundation, a leading national breast cancer nonprofit dedicated to ending cancer disparities for young women—particularly women of color—today announced a collaboration with Bristol Myers Squibb (BMS) focused on expanding access to clinical trials and reducing barriers to participation. This work is part of Tigerlily's ONE in a MILLION campaign (#ONEinaMILLION), which aims to reach one million women with education and empowerment around clinical trials. Clinical research remains essential for developing new treatments and improving standards of care for breast cancer. This campaign helps individuals learn more about and connect to clinical trial opportunities, including studies in triple-negative breast cancer (TNBC). Through this collaboration, Tigerlily Foundation and Bristol Myers Squibb (BMS) are working to increase awareness, education, and engagement around clinical research, with a shared commitment to improving access for communities that have historically been underrepresented in this space. These efforts provide patients with clear, accessible information about their care options while addressing common participation barriers and fostering trust between patients, healthcare providers, and the research community. "Clinical trials should always be presented at the beginning of treatment for patients, and in a way that empowers the patient to participate." said Maricia Cole, Tigerlily ANGEL Advocate. Her perspective highlights the role of early awareness and patient-centered communication in building trust and helping patients better understand their options. "We are proud to collaborate with Bristol Myers Squibb to advance solutions that expand access to clinical trials," said Maimah Karmo, President and CEO of Tigerlily Foundation. "Greater diversity in research leads to better science, more effective treatments, and, ultimately, greater health equity." _This collaboration supports education and awareness about clinical trials and does not constitute_ _medical_ _advice or_ _an_ _endorsement_ _of_ _any_ _specific_ _treatment_ _or_ _study._ _Patients should speak with their healthcare provider about clinical trial options that may be appropriate for them._ About Tigerlily Foundation Tigerlily Foundation is a 501(c)(3) national nonprofit women's health and oncology organization with a mission to end disparities and empower young women and their families by providing education, awareness, advocacy, and hands-on support before, during, and after cancer. Follow Tigerlily Foundation: Instagram Facebook LinkedIn TikTok Media Contact: **Jules** **Annen ****Director,** **Communications** **and** **Health** **Literacy ****\[email protected\]** SOURCE TIGERLILY FOUNDATION ### Related Stocks - [BMY.US](https://longbridge.com/en/quote/BMY.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [PILL.US](https://longbridge.com/en/quote/PILL.US.md) - [IHE.US](https://longbridge.com/en/quote/IHE.US.md) - [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [RXL.US](https://longbridge.com/en/quote/RXL.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [XLV.US](https://longbridge.com/en/quote/XLV.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [VHT.US](https://longbridge.com/en/quote/VHT.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [CELG.RT.US](https://longbridge.com/en/quote/CELG.RT.US.md) ## Related News & Research - [](https://longbridge.com/en/news/286124106.md) - [Tempus AI, Bristol Myers Squibb Expand AI-Driven Clinical Trial Efforts](https://longbridge.com/en/news/286453944.md) - [BMS’ Sotyktu secures EC approval for psoriatic arthritis](https://longbridge.com/en/news/285906740.md) - [NeOnc Advances Glioma Programs and Strengthens Financial Position](https://longbridge.com/en/news/286826865.md) - [Bristol Myers Squibb Touts Pipeline Gains as Shareholders Back Board at Annual Meeting](https://longbridge.com/en/news/285834020.md)